<DOC>
	<DOCNO>NCT02055638</DOCNO>
	<brief_summary>This study design explore safety tolerability , compare activity SRX246 placebo , adult Intermittent Explosive Disorder ( IED ) . Adult Male Female subject current diagnosis IED enrol . After two-week baseline lead-in phase , study subject continue meet enrollment criterion randomize either SRX246 Placebo treatment group . Study subject examine ask answer questionnaire weekly schedule visit throughout trial . The study result determine base change observe study period .</brief_summary>
	<brief_title>Safety , Tolerability Activity SRX246 Adults With Intermittent Explosive Disorder</brief_title>
	<detailed_description>This exploratory Phase II study design examine safety tolerability profile , compare activity novel V1a vasopressin antagonist ( SRX246 ) placebo , adult DSM-5 Intermittent Explosive Disorder ( IED ) . Adult Male Female subject current DSM-5 diagnosis IED enrol . All subject undergo systematic diagnostic assessment DSM-5 Axis I II disorder . Subjects DSM-5 IED ( without current , co-morbid , DSM-5 Major Depression ) whose : ( ) Life History Aggression ( LHA ) score &gt; 12 , ( b ) Overt Aggression Scale Modified ( OAS-M ) `` Irritability '' score &gt; 6 , ( c ) screen OAS-M `` Aggression '' score &gt; 15 , enter two-week baseline lead-in phase . After lead-in phase , study subject continue meet OAS-M criterion randomize one two ( 2 ) treatment condition stratify gender equal number male female assign SRX246 Placebo Groups . Those meet criterion exit protocol time . Treatment Conditions : ( ) 8-week course SRX246 ( 4 week 120 mg bid , 4 week 160 mg bid ) ( b ) 8-week course Placebo , follow one-week `` taper '' withdraw subject study medication . IED subject condition structure diagnostic interview session questionnaires administer throughout trial . Blinding treatment condition maintain use different personnel activity . Analysis change baseline diagnostic measure perform .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Disruptive , Impulse Control , Conduct Disorders</mesh_term>
	<mesh_term>SRX246</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<criteria>Male Female ( Women child bear potential must nonpregnant , nonlactating agree acceptable method contraception . ) Age 21 55 year , inclusive . In good general physical health determine medical history , baseline physical examination , vital sign , clinical laboratory test electrocardiogram ( EKG ) measurement . Current IED DSM5 LHAAggression ≥ 12 . OASM Irritability score ≥ 6 , OASM Total Aggression score ≥ 15 , respectively Visit 1 Mean Irritability Total Aggression score Visit 2 Visit 3 , ≥ 6 ≥ 15 , respectively . Subject willing able sign write informed consent prior receipt study medication begin study procedure . Subject willing able follow instruction , comply protocol requirement make require study visit . Subject positive test alcohol and/or drug abuse screen time study . Presence follow serious active medical condition : Seizure Disorder ( n.b . : history &lt; 2 febrile seizure prior one year age acceptable ) ; Demyelinating Progressive Degenerative Disorders ; central nervous system ( CNS ) Infection ; Progressive Degenerative Neurological Disorder ; Ischemic Heart Disease , Respiratory Disease , Renal Disease ; Liver Disease ; Type I Diabetes ; Malignant Neoplasm ; Hyper HypoCoagulopathy ; Acquired ImmunoDeficiency Syndrome ( AIDS ) . Routine need consumption medication herbal supplement subject unable unwilling discontinue study . Other ongoing psychotherapeutic treatment treatment IED anger begin less three month entry study . Not Current DSM5 IED . LHA score &lt; 12 Visit 1 ( screen ) . OASM Irritability score &lt; 6 OASM Total Aggression score &lt; 15 Visit 1 ( screen ) . Current major depressive episode life history bipolar disorder , schizophrenia , organic mental syndrome , mental retardation . Current DSM5 Substance Use Disorder moderate great severity ( i.e. , ≥ 4 SUD symptom ) . Active suicidal ideation determine clinical assessment ColumbiaSuicide Severity Rating Scale ( CSSRS ) . Evidence outof range laboratory value screen review , approve document clinically significant Study Investigator . A history significant drug allergy systemic allergic disease ( e.g. , urticaria , atopic dermatitis ) , known/suspected hypersensitivity SRX246 . A general medical psychological condition behavior , include current substance dependence abuse , opinion investigator , might permit subject complete study sign inform consent . Unwilling/unable sign inform consent document . Any clinically significant abnormality screen rest 12lead EKG ( e.g. , heart block , conduction disorder , ventricular and/or atrial arrhythmia ) . Any condition clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen , opinion Study Investigator , would make subject unsuitable study put additional risk . Inability understand follow study instruction . Treatment investigational drug within 30 day precede first dose study medication . Women currently breastfeed and/or lactate .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Intermittent Explosive Disorder</keyword>
	<keyword>IED</keyword>
	<keyword>Aggression</keyword>
	<keyword>SRX246</keyword>
	<keyword>Vasopressin 1a Receptor Antagonist</keyword>
	<keyword>V1a</keyword>
</DOC>